Quality of life
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
K G Svalheim, N K Andresen, C Bjerre, B Gilje, E H Jakobsen, R S Falk, B Naume, S Kaasa, J A Kyte
Breast 86 104704
BACKGROUND: The ALICE trial demonstrated that adding atezolizumab to anthracycline-based immunomodulatory chemotherapy improved progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (mTNBC), including those with PD-L1-negative tumors. Here, we report the patient-reported outcome measures (PROMs). METHODS: Patients were randomized to receive chemotherapy plus atezolizumab (atezo-chemo) or chemotherapy plus placebo (placebo-chemo). PROMs were collected at baseline and weeks 9, 17, 25, and 49 using the EORTC QLQ-C15-PAL, Chalder Fatigue Questionnaire (CFQ), and Numeric Rating Scale (NRS) for pain. RESULTS: PROMs were available from 64 of 68 patients. At week 9, mean changes from baseline favored the atezo-chemo arm across all QLQ-C15-PAL domains, CFQ scores, and NRS pain intensity. Time-to-deterioration analyses also favored atezo-chemo, with statistically significant hazard ratios for global quality of life (QoL; HR 0.24), emotional functioning (HR 0.30), and pain (HR 0.20). Pain-a pre-specified cardinal symptom-improved in the atezo-chemo group at all time points. At 12 months, PROMs indicated sustained tolerability. Better baseline PROM scores were associated with improved PFS and overall survival, especially among patients treated with atezolizumab. Patients with >median QoL score at baseline recorded improved PFS when treated with atezolizumab (HR 0.25), while patients with ≤median QoL score did not (HR 1.02). CONCLUSIONS: Adding atezolizumab to the study-chemotherapy in mTNBC improves both PFS and patient-reported quality of life, emotional well-being and symptom control. These findings support continued development of this combination regimen and suggest that baseline quality of life may serve as a useful predictor of immunotherapy benefit. TRIAL REGISTRATION: NCT03164993, May 24th 2017; https://clinicaltrials.gov/ct2/show/record/NCT03164993.
2 个 Figure · 12 个 KM 面板
Fig. 1 Kaplan-Meier plots for time to deterioration in quality of life for [a] all patients, [b] PD-L1-positive and [c] PD-L1-negative, and emotional functioning for [d] all patients, [e] PD-L1-positive, [f] PD-L1-negative. P-values were calculated with log-rank test.
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel B
Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel C
Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel D
Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel E
Panel E 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel F
Panel F 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 Predictive value of QoL score for benefit of atezolizumab. Kaplan-Meier plots for PFS (a) and OS (b–c), in the atezo-chemo compared to placebo-chemo arm, in patients with high (>median) or low (≤median) QoL score. Two patients in the placebo-chemo arm started therapy with PD1/PD-L1 checkpoint inhibitors after end-of-treatment in the ALICE trial. (b) OS, without censoring for any post-study therapy. (c) OS, with censoring at start of post-study PD1/PD-L1 checkpoint inhibitor therapy. Median QoL score was 66.7. P-values calculated with log-rank test. HRs were calculated by cox regression analysis.
Fig. 5 · Panel A
Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel A_2
Panel A_2 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel B
Panel B 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel B_4
Panel B_4 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel C
Panel C 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel C_6
Panel C_6 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。